Month: April 2016

Hepatitis C drug costs leave many without care

pic-boston-globeTwenty years ago, Larry Day learned two dangerous viruses were circulating in his body, HIV and hepatitis C. Both infections came from needles shared during his years as an injecting drug user.

Only one caused him big problems: hepatitis C. That virus destroyed his kidneys, an uncommon complication. Over time, he knew, hepatitis C could lead to cirrhosis and liver cancer. So when drugs came on the market promising to cure him, Day — by then free of illicit drugs — was eager to give them a try.



Man was refused drug that could have saved his life


Insurance refused to cover this man’s prescription for a drug that could have saved his life. This eight minute video is a personal piece about Gene Calvo’s fight for the drug Harvoni produced/edited by his stepson. He was not approved the drug even though he was prescribed it by his doctor. Not getting this drug cost him his life. This piece tells the story. #hepatitisc #harvoni


Important Hep B and C studies to be released in April

Jannsen to present new data

Janssen Sciences Ireland UC announced it and other Janssen affiliates will present 13 research abstracts, covering ongoing work into potential treatments for the hepatitis B virus (HBV) and potential and approved ones for hepatitis C (HCV), at the International Liver Congress of the European Association for the Study of the Liver (EASL 2016), set for April 13–17 in Barcelona, Spain.

“Despite recent advances, the global impact of viral hepatitis remains far reaching with significant unmet needs yet to be addressed. We have come a long way in developing cures for hepatitis C, but further innovation is needed to deliver one treatment suitable for all patient types,” Lawrence M. Blatt, PhD, Global Therapeutic Area head, Infectious Diseases and Vaccines for Janssen Research & Development, said in a press release. “Chronic hepatitis B is a potentially fatal liver disease that requires life-long treatment. There remains no known cure which represents an unmet medical need and we are excited by the opportunity to fully leverage our expertise in this critical disease area in order to bring potentially new treatments to patients.”